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Abstract
Background: Signaling by Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) and Fas ligand (FasL) has been
proposed to contribute to the chemosensitivity of tumor cells treated with various other anti-cancer agents. However, the
importance of these effects and whether there are differences in vitro and in vivo is unclear.
Methodology/Principal Findings: To assess the relative contribution of death receptor pathways to this sensitivity and to
determine whether these effects are intrinsic to the tumor cells, we compared the chemosensitivity of isogenic BJAB human
lymphoma cells where Fas and TRAIL receptors or just TRAIL receptors were inhibited using mutants of the adaptor protein
FADD or by altering the expression of the homeobox transcription factor Six1. Inhibition of TRAIL receptors did not affect in
vitro tumor cell killing by various anti-cancer agents indicating that chemosensitivity is not significantly affected by the
tumor cell-intrinsic activation of death receptor signaling. However, selective inhibition of TRAIL receptor signaling caused
reduced tumor regression and clearance in vivo when tested in a NOD/SCID mouse model.
Conclusions: These data show that TRAIL receptor signaling in tumor cells can determine chemosensitivity in vivo but not
in vitro and thus imply that TRAIL resistance makes tumors less susceptible to conventional cytotoxic anti-cancer drugs as
well as drugs that directly target the TRAIL receptors.
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Introduction
The death receptors DR4 and DR5 activate signaling and
apoptosis in response to the Tumor Necrosis factor-Related
Apoptosis-Inducing Ligand (TRAIL), while Fas/CD95 activates
apoptosis in response to Fas ligand (FasL). These receptors are the
main executioners of the ‘‘extrinsic’’apoptosis pathway that activate
the apoptosis machinery by forming a complex called the Death
Inducing Signaling Complex (DISC). The DISC is formed when a
ligand-bound receptor complex recruits the adaptor protein FADD,
which leads to the recruitment, dimerization [1], and catalytic
activation of caspase-8 [2–4]. Active caspase-8 directly activates the
effector caspase-3 and stimulates the mitochondrial (intrinsic)
apoptosis pathway by cleaving the BH3 protein Bid. This allows
Bid’s translocation in to the mitochondria and Bax/Bak-dependent
release of cytochrome c and other pro-apoptotic proteins, with
subsequent amplification of effector caspase activity. There is
considerable interest in targeting the TRAIL receptors using pro-
apoptotic receptor agonists [2] and clinical trials using recombinant
TRAIL and antibodies that target DR5 or DR4 are underway.
The TRAIL and Fas pathways are important in anti-tumor and
anti-metastasis responses mediated through the immune system
[3,5]. TRAIL signaling mediates T-cell- and natural killer (NK)
cell-dependent metastasis suppression in xenografts [6–9]. Au-
tochthonous models show that deficiency in TRAIL receptor
signaling promotes tumorigenesis [10] and metastasis [11]. Fas
signaling has also been proposed as a mechanism by which NK
cells can eliminate tumor cells [12]. Conversely, Fas signaling can
also be a mechanism by which tumors counteract immune-
mediated anti-tumor responses [13]. Moreover, both Fas [14] and
TRAIL [15] have non-apoptotic signaling activities that promote
tumor progression if the apoptotic response is blocked. Tumor
cells can become resistant to death receptor signaling through
multiple mechanisms [16]. Some of these mechanisms e.g. down-
regulation of FADD [17] or increased expression of the caspase-8-
like protein FLIP [18] affect both Fas and TRAIL receptors
whereas, other mechanisms are more selective. For example,
somatic mutations in DR5 cause a dominant negative phenotype
that blocks TRAIL signaling through DR4 and DR5, but has no
effect on Fas signaling [19]. Similarly, increased expression of the
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arises in the majority of patients with metastatic ovarian or breast
cancer, is associated with poor clinical outcome in multiple tumor
types [20] and causes inhibition of TRAIL but not FasL-induced
apoptosis [21].
Most anti-cancer drugs function by activating the mitochondrial
apoptosis pathway; however, it has been suggested that death
receptor signaling also contributes to the overall anti-tumor
response to diverse chemotherapeutic drugs. Drug and radiation
induced killing of brain tumor [22] and hepatoma [23] cells have
been reported to rely on Fas signaling. Experiments, where
TRAIL signaling was inhibited by silencing DR5 [24] or by
increasing the expression of the decoy receptor DcR2 [25], led to
the conclusion that chemosensitivity to 5-fluorouracil, doxorubi-
cin, and etoposide depends on TRAIL receptor signaling. These
effects have been demonstrated in vitro with cell lines, suggesting
they are intrinsic to tumor cells. These effects can also be achieved
by increased expression of death receptors and/or ligands that
create a tumor cell-intrinsic autocrine signaling loop. Similar
mechanisms of death receptor up-regulation have been proposed
as an explanation for how various cytotoxic chemotherapeutic
agents synergize TRAIL receptor-targeted agonists [26].
However, it is unclear if the Fas and TRAIL receptor pathways
are really important contributors to tumor chemosensitivity. Since
the activation of the mitochondrial apoptosis pathway leads to
efficient cell killing, one would expect that drugs that are able to
activate the mitochondrial pathway (i.e., most anti-cancer agents)
should not require additional death receptor signaling in order to
die, unless the pro-apoptotic signal from the mitochondria was
insufficient to force the cell to cross its apoptotic threshold. It is less
clear if the same considerations apply in vivo, where other inputs
(e.g.,from othercell types)mayplaya role.To addressthisquestion,
we constructed isogenic tumor cell lines that are functional for both
TRAIL and FasL signaling, inhibited for both or inhibited for just
TRAIL signaling. We showthat even in a cell line inwhich blocking
death receptor-induced apoptosis has no detectable effect on the
sensitivity to various chemotherapeutic agents and other apoptotic
inducers in vitro, inhibition of TRAIL receptor signaling in vivo
affects sensitivity to an anti-cancer drug. These data indicate that
the presence of a functional TRAIL receptor apoptosis pathway can
regulate chemosensitivity through tumor cell extrinsic mechanisms.
Results and Discussion
Selective inhibition of death receptor signaling with
FADD-DD mutants
FADD is required for both TRAIL- and FasL-induced
apoptosis. One way signaling can be inhibited by these receptors
is by overexpressing a version of FADD (FADD-DD) that contains
the FADD death domain, but lacks the death effector domain that
binds to caspase-8. This molecule has been thought to inhibit
signaling by competing with endogenous FADD protein for
binding to the activated death receptors. However, based on data
showing that FADD must self-associate via its death effector
domain in order to bind to death receptors, it has been proposed
that the isolated FADD death domain should be unable to bind to
or efficiently inhibit Fas signaling [27]. Therefore, we first tested if
we could obtain effective and selective inhibition of death
receptor-induced apoptosis using FADD-DD and FADD-DD
V108E, a mutant that was selected for its inability to bind to Fas,
while retaining the ability to bind to TRAIL receptors [28]. Dose
response curves (Figure 1A) using FasL or TRAIL with three
isogenic BJAB cell lines expressing, GFP, GFP-FADD-DD or
GFP-FADD-DD (V108E) showed that FADD-DD and FADD-
DD (V108E) effectively inhibited apoptosis induced by TRAIL
and agonistic TRAIL receptor antibodies. However, only the
wildtype FADD-DD molecule inhibited FasL-induced death.
To test if inhibition of receptor-induced apoptosis was due to
binding of the FADD-DD molecules to the activated receptors, we
performed DISC immunoprecipitation experiments (Fig. 1B).
Upon activation of the receptor, FADD-DD was recruited to both
Fas and TRAIL receptors instead of the endogenous FADD
protein, which was recruited in the control cells. The V108E
mutant was recruited only to activated TRAIL receptors. These
data indicate that FADD-DD molecules are effective inhibitors of
death receptor signaling and that their mechanism of action is
through recruitment to the activated receptor in place of
endogenous FADD protein. However, because the level of the
FADD-DD mutants (Fig. 1A) in the cells is about 200-fold higher
than the endogenous FADD protein, while the amount of the
FADD-DD recruited to activated receptors is similar to the
amount of endogenous FADD that is recruited, our data are
consistent with the conclusion of Sandu et al. [27] that the isolated
death domain is less efficiently recruited to the receptors compared
with the endogenous protein. Fig. 1C demonstrates that the
FADD-DD molecule also blocks both FasL and TRAIL-induced
activation of downstream kinase pathways activating JNK and
causes degradation of IkB. The V108E mutant only affects
TRAIL-induced activation of these pathways, which are known to
be activated in a FADD-dependent manner [29].
Inhibition of Fas and TRAIL receptor-induced apoptosis
has no effect on the efficiency of tumor cell killing by
diverse chemotherapeutic agents and apoptotic stimuli
in vitro
To test whether death receptor signaling alters the sensitivity of
tumor cells to other agents, we assessed dose response curves for the
three isogenic cell lines with agents that work by different
mechanisms. Overlapping dose response curves (Fig. 2) showed
that they had no measurable effect on tumor cell killing by various
types of agents that target activities that are relevant for anti-cancer
treatment. We observed this for a toposiomerase inhibitor
(etoposide), histone deactylase inhibitors (oxamflatin, MS275), an
anthracycline (doxorubicin), a proteosome inhibitor (MG132),
DNA damaging agents (UV, temozolomide) and an antimetabolite
(5-fluorouracil). Similarly, there was no effect of FADD-DD or the
V108E mutant on tumor cell killing by general apoptotic stimuli
including the broad-spectrum protein kinase inhibitor staurospor-
ine and increased hyperosmolar stress (sorbitol). MTS assays assess
cell viability over a relatively short term and thus are not truly
comparable to long-term tumor growth responses in vivo. To
ensure that the selective inhibition of TRAIL-induced death
without affecting survival in response to cytotoxic chemotherapy
affected long-term growth, we performed a cell grow back assay by
treating cells for 24 hours with TRAIL or etoposide then washing
out the drug and allowing any surviving cells to grow back. Figure 3
shows that the TRAIL-treated FADD-DD expressing cells
displayed equivalent growth over 7 days to untreated cells whereas
the same cells died in response to etoposide treatment. Thus even
with a more rigorous tumor cell survival assay where any surviving
cells had several days to recover and grow in the absence of drug,
FADD-DD provides no protection against etoposide-induced
death, while providing complete protection against TRAIL.
These data run counter to some other studies. For example, Liu
et al. [25] concluded that increased expression of DcR2, which is a
decoy receptor that selectively inhibits TRAIL signaling, reduced in
vitro chemosensitivity to doxorubicin and etoposide, while Wang
Chemosensitivity and TRAIL
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DR5 conferred resistance to 5-fluorouracil [24]. We therefore
repeated our studies in a colon cancer cell line that was used by
other investigators who reported effects on chemosensitivity.
Figure 4 shows that HCT116 cells expressing FADD-DD were
resistant to both TRAIL and FasL, while the FADD-DD (V108E)
expressing cells were resistant only to TRAIL. However, neither of
these cell lines displayed significantly increased resistance to 5-
fluorouracil, etoposide, or doxorubicin. Additionally, we deter-
mined whether combination treatments with TRAIL and other
anti-cancer agents demonstrated a requirement for death receptor
signaling for optimal activity of the other drug. Combination
treatments using TRAIL with 5-FU, Doxorubicin, or etoposide all
showed increased tumor killing compared with treatment with the
cytotoxic agent alone. However FADD-DD or FADD-DDV108E
expression only blocked the component of the death due to the
death receptor agonist (data not shown). These data indicate that
tumor cell intrinsic signaling through the Fas and TRAIL receptors
does not significantly contribute to the killing activity of the other
stimuli in BJAB cells or in HCT-116 cells.
Inhibition of TRAIL receptor-induced apoptosis promotes
tumor growth and confers chemoresistance in vivo
We next tested whether the FADD-DD constructs conferred an
effect in vivo by growing xenograft tumors with each of the
isogenic BJAB cell lines and treating with one of the agents
(etoposide) that had no effect in vitro. Figure 5 shows that
etoposide treatment caused almost complete tumor regression for
the wildtype BJAB cells; whereas, the cells expressing FADD-DD
or FADD-DD (V108E) displayed significantly less tumor regres-
sion (p,0.05) by etoposide. These data indicate that the same
tumor cells whose sensitivity to etoposide is not affected by FADD-
DD or the V108E mutant in vitro (in both short- and long- term
assays), do display reduced chemosensitivity in vivo. Western
blotting of tumor tissue showed that the tumors retained similar
levels of expression of the GFP-tagged proteins in each case. This
shows that the death receptor-dependent aspect of etoposide
function is achieved through a tumor cell extrinsic mechanism.
Because the FADD-DD and FADD-DD V108E mutants were
equally effective at blocking tumor regression caused by etoposide,
we conclude that signaling through TRAIL receptors alone is
sufficient to cause these effects.
The FADD-DD mutant is a useful tool, because it is highly
specific and effective; however, such dominant negatives have not
been found in human tumors. Therefore, to test whether these
effects also apply when tumor cells are resistant to TRAIL through
a mechanism that is relevant in human tumors, we compared
isogenic BJAB cells that do or do not express the homeobox
transcription factor Six1. Previously, we have shown that Six1
confers TRAIL resistance, but has little effect on FasL sensitivity
Figure 1. Selective inhibition of FasL and TRAIL or TRAIL-induced signaling and apoptosis. In panel A, isogenic BJAB cells expressing GFP
or GFP-FADD-DD and FADD-DDV108E were treated with increasing doses of Fas ligand, TRAIL, or agonistic anti-DR4 and anti-DR5 antibodies. The
differences in responses indicate that both FADD-DD expressing cell lines were resistant to all TRAIL R targeted drugs, but that only FADD-DD
expressing cells are resistant to FasL. In panel B, DISC IP experiments precipitating Fas or DR5 followed by western blotting for casp-8 or FADD
demonstrate an increased recruitment of FADD-DD in place of endogenous FADD to the receptors. Panel C, illustrates that on activation of other
signaling pathways leading to IkB degradation, and JNK phosphorylation, FADD-DD blocks signaling. This block leads to these events for both FasL
and TRAIL, and that FADD-DD V108E blocks signaling only for TRAIL.
doi:10.1371/journal.pone.0014527.g001
Chemosensitivity and TRAIL
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somewhat lesser degree than FADD-DD expressing cells (Fig. 1).
However, these Six1-expressing cells do not demonstrate altered
FasL or etoposide sensitivity in vitro. Furthermore, these cells
displayed reduced chemosensitivity to etoposide (p,0.05) when
tested in vivo (Fig. 6B). Thus, the in vivo dependence of TRAIL
receptor signaling for maximal chemosensitivity to another drug
like etoposide also applies for a TRAIL resistance mechanism that
is commonly found in human tumors and associated with poor
clinical outcomes.
Conclusions
Using isogenic tumor cells that differ only in their ability to
undergo apoptosis in response to Fas or TRAIL receptor
activation, we found that various anti-cancer agents display no
significant difference in their ability to be killed in vitro by anti-
cancer drugs. This shows that, in general, cancer chemotherapy
drugs do not need to work through the death receptors. However,
our results demonstrate a quite different and surprising result in
vivo; etoposide, which was unaffected in vitro by TRAIL receptor
or TRAIL and Fas receptor inhibition was significantly less
effective in vivo and was unable to cause regression of these
tumors. Instead, treatment led to stable tumor size when death
receptor signaling was inhibited in the tumor cells. The lack of
correlation between the in vitro and in vivo experiments carried
out with the same cells indicates that even in tumor cells where
activation of TRAIL receptors is not an important component of
tumor cell killing in response to chemotherapy, tumor regression
and clearance after treatment with a DNA damaging agent
requires TRAIL receptor signaling.
This work suggests that tumors, which have evolved TRAIL
resistance mechanisms [16] such as Six1 overexpression will not
only respond less well to drugs such as Apo2L/TRAIL, lexatumu-
mab, mapatumumab, ApoMab, AMG 655 etc. [2] that directly
Figure 2. FADD-DD and FADD-DD V108E do not inhibit killing by other apoptotic stimuli. Isogenic BJAB cell lines were treated with
increasing doses of etoposide, MS-275, oxamflatin, doxorubicin, MG132, UV, temozolomide, 5-FU, staurosporine or sorbitol as indicated followed by
MTT assay to assess cell viability. All dose response curves overlap for each stimulus.
doi:10.1371/journal.pone.0014527.g002
Chemosensitivity and TRAIL
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conventional cytotoxic chemotherapy. The tumors were grown in
NOD/SCID mice that lack T cells, but not Natural Killer cells or
macrophages,suggesting that these cellsaremost likelythe source of
the TRAIL signal. Recent work has demonstrated the importance
of the adaptive immune system, especially T cells, to the overall
effectiveness of cancer chemotherapy (for review see [30]). Our data
suggest that immune cell-mediated mechanisms working through
TRAIL contribute to efficient tumor clearance after cytotoxic
chemotherapy even without T cell involvement and these effects
may add to any T cell mediated tumor clearance occurring after
chemotherapy treatment. These data suggest that efforts to bypass
TRAIL resistance would improve the efficacy of chemotherapy as
well as improving the usefulness of drugs that are specifically
targeted to TRAIL receptors.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Animal Care and Use Committee of
the University of Colorado, Anschutz Medical Campus (protocol
# 72609(12)1E).
Cell Lines
Parental BJAB cells were described previously [19], the various
resistant cells expressing FADD-DD and FADD-DD V108E were
made by stably expressing the respective cDNAs in pcDNA3.1
puro(+)-GFP. Six1-expressing cells were made by stably expressing
the cDNA in pcDNA3.1 puro (+). All cell clones were derived from
representative single clones isolated by limiting dilution. Cells were
grown in RPMI 1640 with 10% FBS, sodium bicarbonate, and
glucose in a 5% CO2 humidified atmosphere at 37uC. The BJAB
cells used in these studies were DNA profiled using the Identifiler
kit (Applied Biosystems) in January 2010. We have not found any
publication of a DNA profile for BJAB cells, nor are there any
profiles for these cells or ones that have a matching profile in our
own database (CK) or in publicly available databases. These
include the consolidation of the DSMZ, ATCC, JCRB, and Riken
databases of DNA profiles of cell lines now available at DSMZ
website (www.DSMZ.de). Therefore, it is impossible to compare
our sample of these cells to samples of this line used in other
reports. However, this analysis did exclude contamination with
any common cell lines that have been previously profiled. The
profile we obtained for these cells is the following: Amelogenin: X;
CSF1PO: 8,10; D2S1338: 18, 21; D3S1358: 16; D5S818: 12, 13;
D7S820: 10, 11;D8S1179: 14, 15; D13S317: 9,11; D16S539:9, 11;
D18S51: 16, 22; D19S433: 12, 14; D21S11: 27, 28; FGA: 27, 28;
THO1: 7; TPOX: 6,9; vWA: 14, 16.
DISC IP
Fas Ligand—2.5610
7 cells were suspended in 25 ml of culture
medium, incubated with SuperFasLigand (Enzo Life Sciences,
Plymouth Meeting, PA) at 1.25 mg/ml at 37uC for 20 min, washed
in phosphate-buffered saline three times, and then lysed in IP
buffer (150 mM NaCl, 25 mM Tris?Cl, pH 7.5/1% Triton X-
100, 4 mM EDTA) supplemented with complete protease
inhibitors (Roche Applied Science) for 1 hr at 4uC. After the
lysates were centrifuged (15 min at 13,000 rpm), lysates were
precleared for 1 hr at 4uC with Glutathione-Agarose beads
(Sigma, St. Louis, MO). Anti-Flag M2 beads (Sigma, St. Louis,
MO) were added and lysates were incubated at 4uC overnight.
The beads were washed six times with IP buffer and Flag Peptide
(Sigma, St. Louis, MO) was added at 200 ug/ml. Samples were
eluted at room temperature and concentrated. Samples were then
subjected to Western blotting analysis. Anti-DR5—TR2J (Human
Genome Sciences) was crosslinked with anti-human IgG Fc
(Sigma, St. Louis, MO) in a 1:1 ratio for 30 minutes prior to
incubation with cells. Cells (2.5610
7) were suspended in 25 ml of
culture medium, incubated with TR2J/IgG at 1 mg/ml at 4uC for
30 min, transferred to 37uC for another 1 hr, washed in
phosphate-buffered saline three times, and then lysed in IP buffer
for 1 hr at 4uC. After the lysates were centrifuged, lysates were
precipitated at 4uC overnight. The beads were washed six times
with IP buffer supplemented with 0.5 M NaCl and samples were
subjected to Western blotting analysis.
Cell death assays
BJAB cells were plated in 96 well plates at 40,000 cells per well.
TR2J (anti-DR5) and Mapatumumab (anti-DR4) both provided
by Human Genome Sciences were cross-linked with anti-human
IgG Fc for 30 min prior to serial dilution. The following drugs
were prepared according to manufacturer’s instructions and
were applied in serial dilution format: TRAIL (R&D Systems,
Minneapolis, MN), SuperFas Ligand (Enzo Life Sciences, Ply-
mouth Meeting, PA), 5-Fluorouracil (5-FU), Doxorubicin Hydro-
chloride, Etoposide, Oxamflatin, Temozolomide, Sorbitol, MS-
275, and Staurosporine (Sigma, St. Louis, MO), MG132 (EMD
Biosciences, Gibbstown, NJ). UV irradiation was performed in a
UV Stratalinker (Stratagene, La Jolla, CA) in a 24 well plate and
then media and cells were transferred to a 96 well plate for MTS
analysis after 48 hrs. An MTS Assay was performed after 24 hours
incubation according to the manufacturer’s (Promega, Madison,
WI) recommendations. For long-term assays of cell survival/
growth, 1 million cells expressing GFP control or FADD-DD were
treated with TRAIL or etoposide for 24 hours, then washed
and replaced into growth media for 7 days. Cell growth was
Figure 3. FADD-DD blocks TRAIL-induced but not etoposide-
induced death in long-term assays. Isogenic control or FADD-DD
expressing BJAB cells were treated with TRAIL or etoposide as indicated
for 24 hours, then washed and replaced into growth media. Long term
growth of surviving cells was determined by counting viable cells.
Control BJAB cells died rapidly and were unable to recover any long
term growth. Etoposide treated cells were completely unable to recover
growth capacity whether or not FADD-DD was expressed. However
FADD-DD expression protected the TRAIL-treated cells as demonstrated
by overlapping growth curves with the untreated controls.
doi:10.1371/journal.pone.0014527.g003
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GFP, FADD-DD or FADD-DDV108E expression constructs were treated with increasing doses of TRAIL, FasL, etoposide, 5-FU, or doxorubicin as
indicated and cell viability was assessed. FADD-DD and FADD-DDV108E inhibited FasL and TRAIL as in BJAB cells, but had no effect on tumor cell
killing by the chemotherapy drugs.
doi:10.1371/journal.pone.0014527.g004
Figure 5. FADD-DD and FADD-DDV108E reduce the effectiveness of tumor eradication by etoposide in vivo. Panel A, isogenic BJAB
cells expressing GFP control, GFP-FADD-DD and GFP-FADD-DDV108E were implanted subcutaneously and tumors grown for 10 days prior to
treatment with etoposide. Untreated tumors continued to grow. In control BJAB cells, etoposide caused tumor eradication; whereas, in tumors
expressing either FADD-DD or FADD-DDV108E, etoposide treatment led to stabilization of tumor mass but no eradication (p,0.05 by t-test at 18 for
the control versus FADD-DD and FADD-DDV108E expressing cells). Panel B, Western blot of tumor tissue from GFP control, GFP-FADD-DD and GFP-
VFADD-DD V108E demonstrating similar expression of the GFP-tagged protein in all tumors.
doi:10.1371/journal.pone.0014527.g005
Chemosensitivity and TRAIL
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to grow was demonstrated by an increase in the total number of
cells.
Immunoblotting
Cells (1610
6) were harvested and lysates were prepared by
boiling in SDS buffer 5 min prior to gel electrophoresis. Lysates
were resolved on 12% SDS-polyacrylamide gels. Proteins were
transferred to Immobilon-P Transfer Membrane (Millipore
Corporation, Bedford, MA). Blots were blocked with 5% milk in
TBST and incubated with antibodies that recognize IKappaB-
alpha, phospho-JNK, JNK, Caspase 8, Caspase 3 (Cell Signaling
Technologies, Danvers, MA), FADD (BD Biosciences, Franklin
Lakes, NJ). Blots were then incubated with anti-rabbit or anti-
mouse horseradish peroxidase-conjugated secondary antibodies
(Cell Signaling Technologies, Danvers, MA). Detection was
performed using chemiluminescent ECL reagent (Millipore
Corporation, Bedford, MA) and developed on Blue X-Ray film
(Life Science Products, Inc., Frederick, CO).
Transfection of HCT116
Cells (1610
6) were plated in a 6 well dish and transfected with
GFP, GFP-FADD-DD, or GFP-FADD-DD V108E using Lipo-
fectamine 2000 (Life Technologies Corporation, Carlsbad, CA).
Transfection efficiency was verified using fluorescent microscope
24 hrs after transfection. Cells were trypsinized and replated at
16,000 cells per well in a 96 well plate and then allowed to sit
down overnight. Cell death assays were then conducted.
Tumor Treatment studies
Groups of 3–4 NOD/SCID mice were subcutaneously injected
at two sites/mouse with 1610
7 BJAB cells and tumors allowed to
grow to a size of ,200 mm
3 prior to randomization into control or
treatment(IPinjectionofetoposide(15 mg/kgtwiceaweek)groups.
Tumor size was monitored every other day using vernier digital
calipers in three dimensions and calculated as a spheroid tumor
volume (h6w6l60.523). Tumor growth in the treated animals was
compared between groups using t-test. For tumor western blotting,
Paraffin-embedded tumors were deparaffinized in xylene, rehy-
Figure 6. Six1-mediated TRAIL resistance reduces the effectiveness of etoposide in vivo, but not in vitro. Panel A, parental BJAB cells
and BJAB cells expressing Six1 were treated in vitro with increasing doses of TRAIL, FasL and etoposide, and cell viability was assessed by the MTT
assay. Six1 caused TRAIL resistance but had little effect on FasL or etoposide-induced cell death. Panel B illustrates how etoposide treatment of
subcutaneous tumors from BJAB or BJAB-Six1 cells reduces the growth of both tumors relative to untreated controls, but is less effective in the Six1-
expressing cells (* p,0.001 by t-test at day 14 for the control versus Six1 expressing cells).
doi:10.1371/journal.pone.0014527.g006
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Tumors were diced into small pieces and homogenized in RIPA
buffer containing 2% SDS. Samples were heated at 100uC for
20 min and then incubated at 60uC for 2 hrs. Debris was
centrifuged twice to leave the supernatant for western blotting.
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